Geodon reviews bipolar disorder

Ziprasidone (Geodon®, Zeldox®)

Image credit: Adobe Stock

What is ziprasidone used for?

Ziprasidone is used in various conditions including:

  • Schizophrenia and other thought disorders
  • Symptoms associated with autism
  • Bipolar disorder
  • Tourette syndrome

Your doctor may be using this medication for another reason. If you are unclear why this medication is being prescribed, please ask your doctor.

How does ziprasidone work?

Like other atypical antipsychotics, ziprasidone affects the levels of certain chemicals in the brain called dopamine and serotonin. This has been shown to help people who have disorders like schizophrenia and bipolar disorder with their symptoms.

Ziprasidone in children and adolescents

Like many medications used to treat childhood disorders, ziprasidone has not been approved by Health Canada for use in children and adolescents.

Nonetheless, current evidence supports the use of ziprasidone in children and adolescents. Ziprasidone has been shown in a study to be better than placebo (an inactive pill that looks like the medication) for treating bipolar disorder and Tourette syndrome in children and adolescents. Although the majority of information for the use of ziprasidone in schizophrenia is from trials done in adults, more trials in children and adolescents are currently underway.

Thus, when the potential benefits (e.g., reducing symptoms) of using ziprasidone outweigh the potential risks (e.g., the side effects), many doctors may prescribe it “off-label” in children and adolescents.

How should ziprasidone be taken?

Ziprasidone is available as a capsule that is usually taken twice daily. It should be taken with food to improve absorption. This medication should be taken at the same times each day as directed by your doctor. Try to connect taking it with something you do each day (like eating breakfast, or brushing your teeth) so that you don’t forget. Try to avoid alcohol while taking ziprasidone.

Usually, your doctor will start with a low dose of ziprasidone that is best suited to your age and weight. The dose will then be slowly increased over a few weeks based on how you respond. You and your doctor can then discuss the best dosage to stay on based on how you tolerate this medication (how well it helps decrease your symptoms and how you are doing with side effects).

When will ziprasidone start working?

This depends on what you are using it for. Some improvements may be seen in as little as 1 to 2 weeks. However, it can sometimes take up to 6 weeks to see the full benefits of the medication. When ziprasidone is working well, you may notice that your thoughts are clearer and more organized. Agitation may be decreased and hearing voices or seeing things no one else sees (hallucinations) may stop completely or happen much less. Your mood may be more settled and you may see a reduction of intense fears and worries. It is important that you continue taking ziprasidone regularly even if you are feeling well, as it can prevent symptoms from returning. If you are taking this medication to help with symptoms of mood disturbance, you may notice some changes in the first 1 to 2 weeks.

Medications like ziprasidone do not work for everyone. If you are not feeling better within 6 weeks, your doctor may recommend switching you to a different medication.

How long do I have to take ziprasidone?

This depends on the symptoms you have, how frequently they occur, and how long you have had them. Most people will need to take ziprasidone for several months. This allows time for your symptoms to stabilize and for you to regain your functioning. Your doctor will discuss the benefits and risks of taking ziprasidone with you. At this time, you can also discuss how long you might need to take this medication.

Do not increase, decrease, or stop taking this medication without discussing it with your doctor. If you stop taking ziprasidone suddenly, it is possible that your symptoms may return or you may have a bad reaction.

Is ziprasidone addictive?

No, ziprasidone is not addictive and you will not have “cravings” for this medication like you might with nicotine or street drugs. If you and your doctor decide it is best for you to stop taking ziprasidone, your doctor will explain how to safely come off this medication so you don’t feel negative effects as your body adjusts to being without it.

What are the side effects of ziprasidone and what should I do if I get them?

As with most medications, side effects may occur when taking ziprasidone. However, most side effects are mild and temporary. Sometimes the side effects may occur before any of the beneficial effects. It is also possible for some individuals to experience side effects that they feel are concerning or long-lasting. If this occurs, speak to your doctor about ways to manage them. Below are some of the more common side effects of taking this medicine. In brackets are suggested ways to lessen these effects.

Common side effects

Side effects are usually more common when starting a medication or after a dose increase. If any of these side effects is troublesome for you, please discuss them with your doctor, nurse or pharmacist.

  • Agitation, anxiety or restlessness (avoid caffeine from energy drinks, colas and coffee)
  • Blurred vision (this effect often becomes less noticeable over time)
  • Constipation (increase exercise, fluids, vegetables, fruits and fiber)
  • Dizziness (try getting up slowly from a sitting or lying down position)
  • Dry mouth (try chewing sugarless gum, sour candies, ice chips, or popsicles)
  • Headache (try using a pain reliever like acetaminophen (plain Tylenol®))
  • Increase in hunger (avoid high calorie foods)
  • Nausea, upset stomach, poor appetite (try taking the medication with food)
  • Stomach ache (try taking the medication with food)
  • Tiredness, drowsiness, or difficulty falling asleep (speak with your doctor if these effects persist)
  • Weight gain (monitor your food intake, increase your exercise)

Uncommon side effects (e.g., those that occur in less than 5% of patients)

Contact your doctor IMMEDIATELY if you have any of these side effects:

  • Fainting, feeling lightheaded or difficulties with balance
  • Fast or irregular heart beat
  • Feelings of restlessness
  • Fever or excessive sweating
  • Frequent urination accompanied by excessive thirst
  • Rash
  • Seizures
  • Shaking, stiffness or difficulty moving, muscle spasm or stiffness in your throat or tongue
  • Thoughts of hurting yourself, suicide, increased irritability/hostility or feeling worse
  • Weakness or severe muscle pain

Ziprasidone is sometimes associated with a very rare side effect called “neuroleptic malignant syndrome”. The symptoms may include severe muscle stiffness, high fever, increased heart rate and blood pressure, irregular heartbeat (pulse) and sweating. Contact your doctor right away if this occurs.

On rare occasions, medications like ziprasidone have been associated with a side effect called “tardive dyskinesia”. This is a side effect that can sometimes become permanent in patients who take antipsychotic medications. It involves involuntary movements of some muscles in the body like the lips, tongue, toes, hands and neck. Stopping the antipsychotic at the first signs of it occurring or switching to another “atypical” antipsychotic can decrease the chances of having this side effect continue.

Tip: Ziprasidone can make some individuals feel drowsy, dizzy, or slowed down. If you experience these temporary side effects, it is important to avoid operating heavy machinery or driving a car.

What precautions should my doctor and I be aware of when taking ziprasidone?

Tell your doctor or pharmacist if you:

  • Have any allergies, or have experienced a reaction to a medication.
  • Are lactose intolerant (ziprasidone capsules contain lactose).
  • Are taking, or plan to start taking any other prescription or non-prescription medications (including herbal products). Some medications may interact with ziprasidone and should not be taken with ziprasidone. Your doctor may need to change the medications, the doses of your medications, or monitor you carefully for side effects if you are taking medications that interact with ziprasidone.
  • Have a history of low blood pressure, diabetes, kidney disease, blood or bone marrow problems, seizures, or a personal or family history of a heart condition.
  • Miss a period, are pregnant (or planning to become pregnant) or are breast-feeding.
  • Are currently using alcohol or street drugs. These substances may interfere with how well ziprasidone works for you and/or make you feel drowsy.

Tip: When taking this medication, your body may have difficulty regulating your temperature. Make sure you drink lots of fluids or water to avoid becoming dehydrated. You should avoid doing a lot of physical activities on hot days.

What special instructions should I follow while using ziprasidone?

  • Keep all appointments with your doctor and the laboratory. Your doctor may order certain lab tests to check how you are responding to ziprasidone, and to monitor for side effects.
  • Do not allow anyone else to use your medication.

What should I do if I forget to take a dose of ziprasidone?

If you take ziprasidone regularly and you forget to take it, take the missed dose as soon as you remember. However, if it is almost time for your next dose (e.g. within 4 hours), skip the missed dose and continue with your regular dosing schedule. Do NOT double your next dose.

What storage conditions are needed for ziprasidone?

  • Keep this medication in the original container, stored at room temperature away from
  • moisture and heat (e.g. not in the bathroom or kitchen) and protected from light.
  • Keep this medication out of reach and sight of children

Share this document

You may wish to share this information with your family members to help them to understand your treatment options. Since every person’s needs are different, it is important that you follow the advice provided to you by your own doctor, nurse and/or pharmacist and speak to them if you have any questions about this medication.

About this document

Special thanks to the Kelty Centre for Mental Health for permission to adapt this document. The original document was developed by health professionals of BC Mental Health and Addiction Services, and reviewed by the staff of the Kelty Mental Health Centre. French translation provided courtesy of the Ontario Centre of Excellence for Child and Youth Mental Health and the Children’s Hospital of Eastern Ontario (CHEO).

Creative Commons license

You are free to copy and distribute this material unchanged and in its entirety as long as 1) this material is not used in any way that suggests we endorse you or your use of the material, 2) this material is not used for commercial purposes (non-commercial), 3) this material is not altered in any way (no derivative works). View full license at http://creativecommons.org/licenses/by-nc-nd/2.5/ca/. For any other uses, please contact the original rights holder, the Kelty Mental Health Centre.

Disclaimer

Information in this pamphlet is offered ‘as is’ and is meant only to provide general information that supplements, but does not replace the information from your health provider. Always contact a qualified health professional for further information in your specific situation or circumstance.

Geodon

Precautions

Before taking ziprasidone, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: dementia, seizures, low white blood cell count, difficulty swallowing, heart disease (such as coronary artery disease, irregular heartbeat), diabetes (including family history), obesity, breathing trouble during sleep (sleep apnea).

Ziprasidone may cause a condition that affects the heart rhythm (QT prolongation). QT prolongation can rarely cause serious (rarely fatal) fast/irregular heartbeat and other symptoms (such as severe dizziness, fainting) that need medical attention right away.

The risk of QT prolongation may be increased if you have certain medical conditions or are taking other drugs that may cause QT prolongation. Before using ziprasidone, tell your doctor or pharmacist of all the drugs you take and if you have any of the following conditions: certain heart problems (heart failure, recent heart attack, slow heartbeat, QT prolongation in the EKG), family history of certain heart problems (QT prolongation in the EKG, sudden cardiac death).

Low levels of potassium or magnesium in the blood may also increase your risk of QT prolongation. This risk may increase if you use certain drugs (such as diuretics/”water pills”) or if you have conditions such as severe sweating, diarrhea, or vomiting. Talk to your doctor about using ziprasidone safely.

This drug may make you dizzy or drowsy. Alcohol or marijuana (cannabis) can make you more dizzy or drowsy. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Avoid alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).

Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).

This medication may make you sweat less, making you more likely to get heat stroke. Avoid doing things that may cause you to overheat, such as hard work or exercise in hot weather, or using hot tubs. When the weather is hot, drink a lot of fluids and dress lightly. If you overheat, quickly look for a place to cool down and rest. Get medical help right away if you have a fever that does not go away, mental/mood changes, headache, or dizziness.

Older adults may be more sensitive to the side effects of this drug, especially drowsiness, dizziness, lightheadedness, uncontrolled movements, and QT prolongation (see above). Drowsiness, dizziness, and lightheadedness can increase the risk of falling.

During pregnancy, this medication should be used only when clearly needed. Babies born to mothers who have used this drug during the last 3 months of pregnancy may rarely develop symptoms including muscle stiffness or shakiness, drowsiness, feeding/breathing difficulties, or constant crying. If you notice any of these symptoms in your newborn especially during their first month, tell the doctor right away.

Since untreated mental/mood problems (such as schizophrenia, bipolar disorder, depression) can be a serious condition, do not stop taking this medication unless directed by your doctor. If you are planning pregnancy, become pregnant, or think you may be pregnant, immediately discuss with your doctor the benefits and risks of using this medication during pregnancy.

It is unknown if this drug passes into breast milk. Because of the possible risk to the infant, breast-feeding while using this drug is not recommended. Consult your doctor before breast-feeding.

PMC

  • Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry. 1999;156:1686–96.
  • American Psychiatric Association. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington, DC: 1992.
  • American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington, DC: 2000.
  • American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder revision. American Journal of Psychiatry. 2002;159(Suppl):1–50.
  • Ananth J, Burgoyne KS, Niz D, et al. Tardive dyskinesia in 2 patients treated with ziprasidone. Journal of Psychiatry and Neuroscience. 2004;29:467–9.
  • Ananth J, Parameswaran S, Gunatilake S. Side effects of atypical antipsychotic drugs. Current Pharmaceutical Design. 2004a;10:2219–29.
  • Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. Journal of Clinical Psychiatry. 2004b;65:464–70.
  • Apseloff G, Mullet D, Wilner KD, et al. The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium. British Journal of Clinical Pharmacology. 2000;49(Suppl 1):61S–64S.
  • Arbuck DM. 12,800-mg ziprasidone overdose without significant ECG changes. General Hospital Psychiatry. 2005;27:222–3.
  • Baldassano CF, Ballas C, Datto SM, et al. Ziprasidone-associated mania: a case series and review of the mechanism. Bipolar Disorders. 2003;5:72–5.
  • Barnett MS. Ziprasidone monotherapy in pediatric bipolar disorder. Journal of Child and Adolescent, Psychopharmacology. 2004;14:471–7.
  • Berkowitz A. Ziprasidone for dementia in elderly patients: case review. Journal of Psychiatric Practice. 2003;9:469–73.
  • Borovicka MC, Bond LC, Gaughan KM. Ziprasidone- and lithium-induced neuroleptic malignant syndrome. Annals of Pharmacotherapy. 2006;40:139–42.
  • Bowden CL. Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. Journal of Clinical Psychiatry. 2005;3:12–19.
  • Bristol-Myers Squibb Company. Abilify prescribing information. 2006.
  • Caroff SN, Mann SC. Neuroleptic malignant syndrome. Medical Clinics of North America. 1993;77:185–202.
  • Catalano G, Grace JW, Catalano MC, et al. Acute akathisia associated with quetiapine use. Psychosomatics. 2005;46:291–301.
  • Chengappa KN, Suppes T, Berk M. Treatment of bipolar mania with atypical antipsychotics. Expert Review of Neurotherapeutics. 2004;4 (6 Suppl 2):S17–25.
  • Cole SA, Saleem R, Shea WP, et al. Ziprasidone for agitation or psychosis in dementia: four cases. International Journal of Psychiatry in Medicine. 2005;35:91–8.
  • Daniel DG, Brooke S, Warrington LE, et al. IM ziprasidone in agitated patients with bipolar diagnoses. Presented at National Institute of Mental Health New Clinical Drug Evaluation Unit, 44th Annual Meeting; Pheonix, AZ. 2004.
  • Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology. 2001;155:128–34.
  • Endicott J, Cohen J, Nee J, et al. Hamilton Depression Rating Scale. Extracted from regular and change versions of the schedule for affective disorders and schizophrenia. Archives of General Psychiatry. 1981;38:98–103.
  • Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Archives of General Psychiatry. 1978;35:837–44.
  • Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. Journal of Clinical Psychiatry. 2002;4:42–55.
  • Everson G, Lasseter KC, Anderson KE, et al. The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. British Journal of Clinical Pharmacology. 2000;49(Suppl 1):21S–26S.
  • Gentile S. Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder. Journal of Clinical Psychopharmacology. 2007;27(1):35–45.
  • Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Safety. 2006;29(4):303–19.
  • Ghaemi SN, Hsu DJ, Rosenquist KJ, et al. Extrapyramidal side effects with atypical neuroleptics in bipolar disorder. Progress in Neuro Psychopharmacology and Biological Psychiatry. 2006;30:209–13.
  • Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. Journal of Clinical Psychopharmacology. 1997;17:377–89.
  • Gomez-Criado MS, Bernardo M, Florez T, et al. Ziprasidone overdose: cases recorded in the database of Pfizer-Spain and literature review. Pharmacotherapy. 2005;25:1660–5.
  • Gray NS. Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson’s disease: a diagnostic challenge. Human Psychopharmacology. 2004;19:205–7.
  • Greco KE, Tune LE, Brown FW, et al. A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients. Journal of Clinical Psychiatry. 2005;66:928–9.
  • Guy W. Early clinical drug evaluation manual. Washington, DC: United States Department of Health, Education, and Welfare; 1976.
  • Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24:62–9.
  • Heinrich TW, Biblo LA, Schneider J. Torsades de pointes associated with ziprasidone. Psychosomatics. 2006;47:264–8.
  • Hirsch SR, Kissling W, Bauml J, et al. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. Journal of Clinical Psychiatry. 2002;63:516–23.
  • Isometsa ET, Henriksson MM, Aro HM, et al. Suicide in bipolar disorder in Finland. American Journal of Psychiatry. 1994;151:1020–4.
  • Janssen. Risperdal prescribing information. 2007.
  • Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Archives of General Psychiatry. 1982;39:473–81.
  • Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987;13:261–76.
  • Keck ME, Muller MB, Binder EB, et al. Ziprasidone-related tardive dyskinesia. American Journal of Psychiatry. 2004;161:175–6.
  • Keck PE, Jr, Pope HG, Jr, Cohen BM, et al. Risk factors for neuroleptic malignant syndrome. A case-control study. Archives of General Psychiatry. 1989;46:914–8.
  • Keck PE, Jr, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. American Journal of Psychiatry. 2003;160:741–8.
  • Keck PE, Jr, Warrington L, Potkin S, et al. Efficacy and safety of ziprasidone in bipolar disorder: short- and long-term data. 157th annual meeting of the American Psychiatric Association; New York, NY. 2004.
  • Kowatch RA, DelBello MP. Pediatric bipolar disorder: emerging diagnostic and treatment approaches. Child and Adolescent Psychiatric Clinics of North America. 2006;15:73–108.
  • Leibold J, Patel V, Hasan RA. Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clinical Therapeutics. 2004;26:1105–8.
  • Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine. 2005;353:1209–23.
  • Levy WO, Robichaux-Keene NR, Nunez C. No significant QTc interval changes with high-dose ziprasidone: a case series. Journal of Psychiatric Practice. 2004;10:227–32.
  • Lipinski JF, Jr, Mallya G, Zimmerman P, Pope HG., Jr Fluoxetine-induced akathisia: clinical and theoretical implications. Journal of Clinical Psychiatry. 1989;50:339–42.
  • Leso L, Schwartz TL. Ziprasidone treatment of delirium. Psychosomatics. 2002;43:61–2.
  • Marken PA, Pies RW. Emerging treatments for bipolar disorder: safety and adverse effect profiles. Annals of Pharmacotherapy. 2006;40:276–85.
  • Mason MN, Johnson CE, Piasecki M. Ziprasidone-induced acute dystonia. American Journal of Psychiatry. 2005;162:625–6.
  • McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. Journal of Clinical Psychiatry. 2005;3:28–36.
  • McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using typical antipsychotic drugs: a prospective comparative study. Journal of Clinical Psychiatry. 2005;66:444–9.
  • Mendhekar DN. Ziprasidone-induced tardive dyskinesia. Canadian Journal of Psychiatry Revue Canadienne de Psychiatrie. 2005;50:567–8.
  • Miceli JJ, Wilner KD, Hansen RA, et al. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. British Journal of Clinical Pharmacology. 2000;49(Suppl 1):5S–13S.
  • Michalopoulou PG, Lykouras L. Manic/hypomanic symptoms induced by atypical antipsychotics: a review of the reported cases. Progress in Neuro Psychopharmacology and Biological Psychiatry. 2006;30:549–64.
  • Miodownik C, Hausmann M, Frolova K, et al. Lithium intoxication associated with intramuscular ziprasidone in schizoaffective patients. Clinical Neuropharmacology. 2005;28:295–7.
  • Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry. 1979;134:382–9.
  • Mukherjee S, Rosen AM, Caracci G, et al. Persistent tardive dyskinesia in bipolar patients. Archives of General Psychiatry. 1986;43:342–6.
  • Murty RG, Mistry SG, Chacko RC, et al. Neuroleptic Malignant Syndrome with ziprasidone. Journal of Clinical Psychopharmacology. 2002;22:624–6.
  • Nasrallah HA, Churchill CM, Hamdan-Allan GA. Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia. American Journal of Psychiatry. 1988;145:1455–6.
  • Nemeroff CB, Lieberman JA, Weiden PJ, et al. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectrums. 2005;10:s1–20.
  • Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Supp 1):1–93.
  • Ozen ME, Yumru M, Savas HA, et al. Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment. World Journal of Biological Psychiatry. 2007;8:42–4.
  • Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. Journal of Clinical Psychiatry. 2004;65:217–21.
  • Patel NC, Keck PE., Jr Ziprasidone: efficacy and safety in patients with bipolar disorder. Expert Review of Neurotherapeutics. 2006;6:1129–38.
  • Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. Journal of Clinical Psychiatry. 2006;67:509–16.
  • Pfizer. Geodon prescribing information. 2007.
  • Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Safety. 2005;28:191–208.
  • Potkin SG, Keck PE, Jr, Segal S, et al. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. Journal of Clinical Psychopharmacology. 2005;25:301–10.
  • Potkin SG, Keck PE, Giller E, et al. Ziprasidone in bipolar mania: efficacy across patient subgroups. Presented at the 157th annual meeting of the American Psychiatric Association; New York, NY. 2004.
  • Preval H, Klotz SG, Southard R, et al. Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study. General Hospital Psychiatry. 2005;27:140–4.
  • Prieto T, Benabarre A, Bernardo M. The highest intentional ziprasidone overdose was not fatal. Acta Psychiatrica Scandinavica. 2005;112:79–80.
  • Ramos AE, Shytle RD, Silver AA, et al. Ziprasidone-induced oculogyric crisis. Journal of the American Academy of Child and Adolescent Psychiatry. 2003;42:1013–4.
  • Rosenquist KJ, Walker SS, Ghaemi SN. Tardive dyskinesia and ziprasidone. American Journal of Psychiatry. 2002;159:1436.
  • Schmidt AW, Lebel LA, Howard HR, Jr, et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. European Journal of Pharmacology. 2001;425:197–201.
  • Simpson SG, Jamison KR. The risk of suicide in patients with bipolar disorders. Journal of Clinical Psychiatry. 1999;2:53–6.
  • Sprague DA, Loewen PS, Raymond CB. Selection of atypical antipsychotics for the management of schizophrenia. Annals of Pharmacotherapy. 2004;38(2):313–9.
  • Suppes T, Dennehy EB. TIMA procedural manual. Vol. 2001 Dallas: 2001. Bipolar disorder algorithms.
  • Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. Journal of Clinical Psychiatry. 2005;66:870–86.
  • Swift RH, Harrigan EP, Cappelleri JC, et al. Validation of the behavioral activity rating scale (BARS): a novel measure of activity in agitated patients. Journal of Psychiatric Research. 2002;36:87–95.
  • Vieta E. Bipolar mixed states and their treatment. Expert Review of Neurotherapeutics. 2005;5:63–8.
  • Vornik LA, Hirschfeld RM. Bipolar disorder: quality of life and the impact of atypical antipsychotics. American Journal of Managed Care. 2005;11(9 Suppl):S275–80.
  • Weiden PJ, Daniel DG, Simpson G, et al. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. Journal of Clinical Psychopharmacology. 2003;23:595–600.
  • Weinstein SK, Adler CM, Strakowski SM. Ziprasidone-induced acute dystonic reactions in patients with bipolar disorder. Journal of Clinical Psychiatry. 2006;67:327–8.
  • Weisler R, Dunn J, English P. Ziprasidone in adjunctive treatment of acute bipolar mania: randomized, double-blind, placebo-controlled trial. 55th Institute on Psychiatric Services Meeting; Boston, MA. 2003.
  • Weisler R, Warrington L, Dunn J, et al. Adjunctive ziprasidone in bipolar mania: short- and long-term data. 157th annual meeting of the American Psychiatric Association; New York, NY. 2004.
  • Wirshing WC. Movement disorders associated with neuroleptic treatment. Journal of Clinical Psychiatry. 2001;21:15–8.
  • Yang SH, McNeely MJ. Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone. American Journal of Psychiatry. 2002;159:1435.
  • Young CC, Lujan E. Intravenous ziprasidone for treatment of delirium in the intensive care unit. Anesthesiology. 2004;101(3):794–5.
  • Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry. 1978;133:429–35.

ziprasidone (Rx)

Black Box Warnings

Not approved for dementia-related psychosis; patients with dementia-related psychosis who are treated with antipsychotic drugs are at increased risk of death, as shown in short-term controlled trials; deaths in these trials appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature

Not approved for the treatment of dementia-related psychosis

Contraindications

Documented hypersensitivity

Any drugs or conditions that prolong QT interval

Recent acute myocardial infarction

Uncompensated heart failure

Cautions

Seizure disorders; may cause hypotension, EPS, somnolence, and sensory instability, which could lead to falls and, consequently, fractures or other injuries; for patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy

Atypical antipsychotics have been associated with metabolic changes (eg, hyperglycemia, dyslipidemia, and body weight gain) that may increase cardiovascular/cerebrovascular risk

Hyperglycemia may occur and in some cases may be extreme, resulting in ketoacidosis, hyperosmolar coma, or death; monitor blood glucose of high-risk patients

Neuroleptic malignant syndrome reported with antipsychotic drugs

Tardive dyskinesia, acute dystonic reactions, pseudoparkinsonism, or akathisia may develop acutely or chronically

Discontinue if rash develops without an identified cause

Drug reaction with eosinophilia and systemic symptoms (DRESS) reported; DRESS consists of combination of three or more of the following: cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, fever, lymphadenopathy and one or more systemic complications such as hepatitis, nephritis, pneumonitis, myocarditis, and pericarditis; DRESS is sometimes fatal; discontinue therapy if DRESS suspected

Cutaneous adverse reactions, such as Stevens-Johnson syndrome, reported; severe cutaneous adverse reactions are sometimes fatal; discontinue therapy if suspected

Rare cases of priapism reported

FDA warning regarding off-label use for dementia in elderly (see Black Box Warnings)

May cause orthostatic hypotension

Suicide attempt is inherent in psychotic illness or bipolar disorder, close supervision of high-risk patients should accompany drug therapy

Dopamine2 antagonists may elevate prolactin levels; long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density

Leukopenia/neutropenia and agranulocytosis reported; possible risk factors for leukopenia/neutropenia include preexisting low white blood cell (WBC) count and history of drug-induced leukopenia/neutropenia

If patient has history of clinically significant low WBC count or drug-induced leukopenia/neutropenia, monitor complete blood count (CBC) frequently during first few months of therapy; discontinue drug at first sign of clinically significant WBC decline

Antipsychotic agents have been associated with esophageal dysmotility and aspiration; use caution in patients at risk of pneumonia

May cause QTc prolongation, which has been associated with development of malignant ventricular arrhythmias (torsade de pointes) and sudden death; discontinue therapy in patients with persistent QTc intervals >500 msec; avoid hypokalemia or hypomagnesemia

Moderate to highly sedative; use caution when required to operate heavy machinery

May cause core body temperature regulation impairment; use caution with heat exposure, strenuous exercise, dehydration, or taking medications with anticholinergic effects

Make electrolyte imbalance corrections, especially hypomagnesemia or hypokalemia before and throughout therapy

Use with caution in hepatic impairment

Escitalopram plus adjunctive ziprasidone may lead to weight gain and akathisia and require additional monitoring of patients with major depressive disorder (MDD), but ziprasidone augmentation appears safe overall, according to research published in the Journal of Clinical Psychiatry.

David Mischoulon, MD, PhD, from the Depression Clinical and Research Program at Massachusetts General Hospital in Boston, and colleagues conducted a randomized, double-blind, placebo-controlled study of patients with persistent MDD (Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder That Do Not Sufficiently Respond to Treatment With SSRIs; ClinicalTrials.gov identifier: NCT00633399). Outpatients (n=139) were recruited after an 8-week open-label trial of escitalopram.

During the initial 8-week study period, participants from 3 academic medical centers in Boston, Massachusetts; Birmingham, Alabama; and Nashville, Tennessee, received escitalopram 10 to 30 mg/day. During the first 4 weeks, escitalopram doses increased by 10 mg/week, stabilizing at week 4. After enrollment in the 8-week open-label expansion, participants randomly received either adjunctive ziprasidone (escitalopram plus ziprasidone 20-80 mg twice daily; n=71) or escitalopram plus placebo (n=68). Mean doses of escitalopram were 21±5.8 mg/day and 19.2±3.1 mg/day in the ziprasidone and placebo groups, respectively.

Body mass index, weight, low-density lipoprotein-cholesterol and high-density lipoprotein-cholesterol, triglycerides, fasting glucose, HbA1c, thyroid-stimulating hormone, and prolactin levels were assessed at baseline and again at the conclusion of the double-blind phase. Measurements for all parameters were comparable at baseline between both groups (P >.05). No significant changes were recorded in most measures by week 8, although ziprasidone therapy resulted in a “significantly greater” weight increase than placebo (net difference, 2.5 kg; P =.03).

Although baseline QTc measures were also similar between groups, QTc increased by a mean 8.8 milliseconds by week 8 in the ziprasidone group (P =.06), so a significant association was noted between ziprasidone dose and QTc prolongation.

Patients in the ziprasidone group experienced a significantly higher baseline Barnes Akathisia Scale score for 1 item (objective); the other 3 items (subjective awareness of restlessness, distress related to restlessness, and global clinical assessment of akathisia) were similar between groups. During the study period, Barnes Akathisia Scale scores for item 4 increased in the ziprasidone group and decreased in the placebo group (P =.01).

“Adjunctive ziprasidone when combined with the escitalopram in MDD patients…demonstrated a mild increase in QTc that is deemed unlikely to be of broad clinical relevance,” the researchers wrote. “The positive efficacy findings for this combination supported its use as an effective augmentation of an SSRI, and our current results also support relative safety of the combination therapy.”

“However, in view of the developing concerns and warning about SSRIs and QTc prolongation, clinicians should carefully weigh the pros and cons of this combination,” they concluded.

Limitations

The current study focused on efficacy, safety, and tolerability of adjunctive ziprasidone; it is unclear whether results would have been different if other antidepressants were used in conjunction with ziprasidone.

  • Multiple inclusion and exclusion criteria were included in the current study, and it is unknown whether more cardiovascular or metabolic effects would have been seen in patients who did not meet inclusion criteria.

Drs Mischoulon, Shelton, Bobo, Fava, and Papakostas report receiving a variety of research support, consulting, and speaking honoraria and grant funding from Pfizer and Forest Pharmaceuticals.

Reference

Mischoulon D, Shelton R, Baer L, et al. Ziprasidone augmentation of escitalopram for major depressive disorder: cardiac, endocrine, metabolic, and motoric effects in a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. doi: 10.4088/JCP.15m10426

Ziprasidone Augmentation May Have Benefits in Depression

The antipsychotic ziprasidone may be an efficacious adjunct to escitalopram for patients with non-psychotic unipolar major depressive disorder, according to a study published in the American Journal of Psychiatry.

George I. Papakostas, MD, and colleagues conducted a randomized, double-blind, parallel-group, placebo-controlled trial that included 139 participants at three academic medical centers. Participants were randomly assigned to one of two groups during the 8-week study—one group received escitalopram with adjunctive ziprasidone and the other group received escitalopram and adjunctive placebo.

Participants were followed-up weekly for 8 weeks, and the primary outcome was at least a 50% reduction in score on the Hamilton Depression Rating Scale (HAM-D). After 8 weeks, 35.2% of participants improved in the group with adjunctive ziprasidone compared with 20.5% in the placebo group.

Some secondary outcome measures also were greater in the adjunctive ziprasidone group. Participants improved more on the Hamilton Anxiety Rating Scale (HAM-A), though they did not improve on the Visual Analog for Pain score.

While none of the patients in the placebo group stopped treatment due to intolerance, 14% of patients in the adjunctive ziprasidone group discontinued treatment for that reason.

“These results suggest that, similar to other atypical antipsychotic agents, adjunctive ziprasidone can represent a useful treatment option for patients with major depressive disorder,” the study’s authors concluded.

—Lauren LeBano

Reference

Ziprasidone as Adjunctive Therapy in Severe Bipolar Patients Treated with Clozapine

Abstract

Aim. To confirm the efficacy and tolerability of ziprasidone as adjunctive therapy in bipolar patients partially responding to clozapine or with persisting negative symptoms, overweight, or with metabolic syndrome. Methods. Eight patients with psychotic bipolar disorder were tested with the BPRS, the HAM-D, and the CGI at T0 and retested after 2 weeks (T1). Plasma clozapine and norclozapine levels and BMI were tested at T0 and T1. Results. Ziprasidone was well tolerated by all the patients. BPRS and HAM-D scores were reduced in all patients. BMI was reduced in patients with a BMI at T0 higher than 25. Plasma levels of clozapine and norclozapine showed an irregular course.

1. Introduction

Atypical antipsychotics (also known as second generation antipsychotics, SGAs) have proven effective in the treatment of schizophrenia and schizoaffective disorder yielding improvements in both positive and negative symptoms .

Many SGAs are also indicated for the treatment of the different phases of bipolar disorder (BD) (i.e. acute mania and depression and maintenance) in monotherapy and in association with mood stabilizers. The SGAs vary widely in their efficacy/tolerability profiles allowing a better personalization of pharmacotherapy .

SGAs have represented a meaningful improvement in clinical management of BD but a substantial percentage of patients keep on experiencing relapses, continuous cycling, persistent affective and psychotic symptoms, and functional deterioration .

Clozapine, the “gold standard” of SGAs, has never been approved for the treatment of bipolar disorder, though it has showed efficacy in acute mania and in the treatment of severe psychotic bipolar disorder. This latter has been suggested to represent a possible intermediate clinical phenotype placed in the continuum of major psychoses bridging typical bipolar disorder to schizophrenia through schizoaffective disorder .

A significant percentage of patients with severe psychotic bipolar disorder exhibit poor or incomplete response to usual monotherapy and combination treatments of adequate dosages and duration. Clozapine has been proposed as a suitable rescue choice to manage such complex conditions including uncontrollable mood instability, agitation, insomnia, psychosis, and aggressiveness. Unfortunately, even the addition of clozapine to the therapeutic strategy often leads only to a partial response . Moreover, clozapine treatment is burdened with several short- and longer-term side effects such as sialorrhoea, oversedation, increased appetite leading to weight gain, new-onset diabetes, dyslipidemia and metabolic syndrome .

Many studies focusing mostly on schizophrenia samples have proposed distinct adjunctive antipsychotics in order to promote clinical remission, to attempt a clozapine dose reduction, and/or to mitigate its side effects .

Although the combination of two or more antipsychotics in bipolar disorder is poorly documented and, to our knowledge, not supported by randomized clinical trials, it is a common strategy in clinical practice : about 15% of psychotic bipolar outpatients and 50% of inpatients receive more than one antipsychotic .

We have previously reported that the augmentation of clozapine with aripiprazole may be safe and effective in severe psychotic schizoaffective and bipolar disorder which failed to respond to SGAs .

Ziprasidone is an atypical antipsychotic recently introduced in the Italian market, approved for the treatment of schizophrenia in adults and also for the treatment of bipolar manic or mixed episodes of moderate severity in adults, adolescents, and children (aged between 10 and 17), with a reported low potential for extrapyramidal side effects.

Given its antagonistic activity on serotonin 5-HT2A, 5-HT1D, and 5-HT2C receptors and the agonist partial activity on 5-HT1A receptors as well as the moderate in vitro-inhibitory activity on serotonin and noradrenaline transporters, ziprasidone has been suggested to display efficacy on depressive and negative symptoms . Ziprasidone, in conjunction with mood stabilizers, could promisingly offer additional mood regulating, antidepressant, and anxiolytic actions .

Its low affinity for H1 histaminergic, alpha1 adrenergic, and M1 muscarinic receptors predicts a safe tolerability profile with a low potential, respectively, for weight gain, hyperglycemia, cholesterol and triglyceride dysregulation, orthostatic hypotension and cardiovascular side effects, sedation, and cognitive impairment . Because of this favourable side effect profile and low risk of pharmacologic interactions, ziprasidone is a suitable candidate for clozapine augmentation.

The association of ziprasidone to an ongoing clozapine treatment has proven effective in severe psychotic patients bringing about improvements of negative/cognitive symptoms and of clozapine related side effects, with only a minor QTc interval prolongation .

Aims of this paper are to report on the potential efficacy and tolerability of the clozapine-ziprasidone association in a case series of severe psychotic bipolar patients resistant to previous medication trials and to provide preliminary data on possible pharmacokinetic interactions between the two antipsychotics.

2. Material and Methods

Patients were recruited in the Inpatient Psychiatric Unit of the Department of Psychiatry at Pisa University. All patients received a diagnosis of bipolar disorder with psychotic symptoms by the treating clinician according to the DSM-IV criteria .

Eligibility criteria were the following: (1) age of 18–65 years, (2) resistance/inadequate response to at least two trials of mood stabilizers (i.e. lithium salts, valproic acid, and carbamazepine) and/or of antipsychotics prescribed at adequate dosages, for at least six months, (3) treatment with clozapine at least six months ago, (4) relevant mood swings associated with persistent psychotic symptoms despite the treatment with clozapine, (5) no contraindications to ziprasidone treatment (e.g., prolonged QTc interval), (6) normal bone marrow and hepatic and renal functions, (7) capability to attend follow-up visits, and (8) proved compliance to treatment as indicated by blood levels monitoring.

On the contrary, exclusion criteria were as follows: (1) history of drug abuse/dependence within six months from enrolment, (2) diagnosis of neurologic disorders such as Parkinson’s disease, epilepsy, and myasthenia gravis, (3) jaundice or haematological diseases, (4) pregnancy or breast-feeding, and (5) current major depression.

Administration of other psychotropic medications other than clozapine and ziprasidone was allowed as clinically needed and recorded as well.

According to usual monitoring protocols implemented at our Inpatient Psychiatric Unit, patients underwent assessments with a number of clinical rating scales, systematic recording of side effects, laboratory tests, body mass index (BMI) monitoring, and measurement of clozapine and norclozapine plasma levels.

Clozapine and norclozapine plasma levels recorded within patients’ case report forms were considered for the aims of the present study on the day before (T0) and 15 days after (T1) ziprasidone introduction. The measurement of plasma drug levels was performed in fasting condition three hours after the clozapine morning dose, which corresponds approximately to the time of clozapine peak concentration. BMI and concomitant therapies information was collected at T0 and T1 as well as any unwanted effects of medications. All patients provided written consent to the review of their case histories.

2.1. Efficacy and Tolerability Assessments

The Mini International Neuropsychiatric Interview (M.I.N.I.) was administered at T0 to confirm diagnosis. Clinical features and disease severity were evaluated by means of the Brief Psychiatric Rating Scale 24 items (BPRS), the Hamilton Depressive Rating Scale (HAM-D), and the Clinical Global Improvement (CGI).

2.2. Laboratory Analysis

Blood samples (5 mL) for clozapine plasma levels measurement were withdrawn from a peripheral vein of the forearm, collected within heparinized tubes, and immediately centrifuged. Plasma was stored at −20°C until the actual measurement of drug levels.

Plasma concentrations of clozapine and its active metabolite were determined by the high performance liquid chromatography (HPLC) method, using a commercially available kit (Chromsystems, Munchen, Germany), following the instructions of manufacturers. The clozapine/norclozapine plasma concentration ratio was calculated as an index of drug metabolism in patients, while levels of the drug and the metabolite were normalized by the daily clozapine dose in order to reduce interpatient variability.

2.3. Statistical Analysis

BPRS, HAM-D, and CGI scores before and after ziprasidone association were compared using the Wilcoxon signed rank test. Statistical significance was set at 2-sided (StataCorp. 2007. Stata Statistical Software: Release 10. College Station, TX: StataCorp LP).

3. Results

3.1. Clinical Characteristics

Eight patients (6 males and 2 females) were enrolled from May 2011 to September 2011. All subjects were diagnosed with bipolar disorder, mixed episode with psychotic features. One patient received the additional diagnosis of social phobia and one patient of comorbid panic disorder.

Before ziprasidone augmentation, patients had been assuming clozapine at a mean dosage of 140.6 mg daily (range 50–250 mg daily) for at least 6 months. All patients were at clozapine steady state and previous controls had demonstrated stable plasma concentrations. Moreover, all patients had been taking all the other drugs (see Table 3) for at least a period of 30 days before the study initiation.

Ziprasidone was added to the ongoing therapy starting at a dose of 40 mg twice daily up to a final total daily dose of 120–160 mg/day (mean dose: 155 mg/day).

3.2. Metabolic Parameters

Cholesterol and triglycerides plasma levels were tested at T0. No patients showed severe metabolic dysfunctions (see Table 1). One patient had a second grade obesity (BMI 36.6), two patients had a first grade obesity (BMI of 30 and 32, resp.), three were overweight (BMI of 27.7, 27, and 26, resp.), and two had a normal BMI (see Table 4).

Patients Cholesterol levels
mg/dL T0
Cholesterol levels
mg/dL T1
LDL
mg/dL T0
LDL
mg/dL T1
HDL
mg/dL T0
HDL
mg/dL T1
Triglycerides
mg/dL T0
Triglycerides
mg/dL T1
BMI T0 BMI T1
1 174 112 41 78 36.2 33.9
2 168 108 111 60 28 20 211 166 32.2 31.4
3 147 85 41 144 27 26.6
4 113 49 30 187 27.7 27.7
5 218 184 139 126 43 36 183 112 30 29.1
6 117 62 184 24.5 25.1
7 189 109 53 113 26.2 25.7
8 165 105 37 84 23.6 24.3

Table 1 Metabolic parameters before and after the addition of ziprasidone.

3.3. Clozapine, Norclozapine Plasma Levels and Clozapine/Norclozapine Ratio

Mean plasma levels of clozapine and norclozapine at T0 were 0.172 mg/L and 0.143 mg/L, respectively. Mean plasma levels of clozapine and norclozapine at T1 were 0.304 mg/L and 0.119 mg/L, respectively.

After the adjunction of ziprasidone the clozapine dosage was reduced in 2 patients and increased in other 3 patients. As a whole, plasma levels of clozapine and norclozapine fluctuated for each patient irregularly and irrespective of drug dosage modifications.

3.4. Concomitant Treatments

After the augmentation with ziprasidone concomitant psychotropic treatments were reduced in all patients with the exception of one (see Table 2).

Patients Concomitant treatments at T0 Concomitant treatments at T1
1 Haloperidol 9 mg
Chlorpromazine 50 mg
Chlordemethyldiazepam 1.8 mg
Bisoprolol 10 mg
Haloperidol 9 mg
Chlorpromazine 50 mg
Chlordemethyldiazepam 1.8 mg
Bisoprolol 10 mg
2 Haloperidol 3 mg
Escitalopram 10 mg
Fat acid 1000 mg
Fenofibrate 145 mg
Fat acid 1000 mg
Fenofibrate 145 mg
3 Orphenadrine 4 mg
Clonazepam 1.5 mg
Haloperidol 4 mg
Levetiracetam 500 mg
Orphenadrine 4 mg
Clonazepam 1.5 mg
Levetiracetam 500 mg
4 Haloperidol 1.2 mg
Valproic acid 600 mg
Lithium carbonate 900 mg
Orphenadrine 4 mg
Haloperidol 1.2 mg
Valproic acid 600 mg
Orphenadrine 4 mg
5 Lithium carbonate 600 mg
Haloperidol 2.5 mg
Citalopram 20 mg
Levotiroxin 50 mcg
Allopurinol 150 mg
Clonazepam 1 mg
Lithium carbonate 600 mg
Levotiroxin 50 mcg 
Citalopram 20 mg
6 Haloperidol 3 mg
Lithium carbonate 300 mg
Chlordemethyldiazepam 0.8 mg
Ramipril 5 mg
Atenolol 50 mg
Chlordemethyldiazepam 0.8 mg
Ramipril 5 mg
7 Bromperidol 2.5 mg
Lithium Carbonate 300 mg
Lithium Carbonate 300 mg
8 Lithium Carbonate 600 mg
Valproic acid 1500 mg
Lithium Carbonate 600 mg
Valproic acid 1250 mg
ECT

Table 2 Concomitant treatments at T0 and T1.

Patients BPRS HAM-D CGI
1 13.54% 16.4% 28.5%
2 10.4% 8.9% 14.2%
3 3.6% −3% 14.3%
4 11.9% 13.4% 14.2%
5 14.3% 6% 14.3%
6 4% 10.4% 14.2%
7 13.6% 0% 14.3%
8 17.5% 12% 28.6%

Table 3 Percentage of improvement at BPRS, HAM-D, and CGI. Table 4 Percentage of BMI improvement after ziprasidone augmentation.

3.5. Severity Assessment

At T1, the majority of the patients displayed a significant improvement of symptom severity as assessed by BPRS (, ), CGI (, ), and HAM-D (, ) rating scales. Specifically, the mean BPRS anxiety depression domain score decreased from 11.4 at T0 to 8.1 at T1; the anergy domain varied from 12.9 to 8.7; the thought disorder domain decreased from 13.4 to 9.5; the psychomotricity domain changed from 5.9 to 4.75; lastly, an improvement from 7.7 at T0 to 5.7 at T1 was detected in the suspiciousness hostility domain.

One patient showed an HAM-D score worsening at T1 due to a higher level of psychic and somatic anxiety. This patient was the one diagnosed with comorbid panic disorder (Table 3).

3.6. Side Effects

No treatment emergent side effects were apparently attributable to ziprasidone prescription.

4. Supplementary Data

The reduction of valproic acid was possible in one patient (number 8). Two patients needed to stop lithium therapy because of the onset of psoriasis and the worsening of glomerulonephritis, respectively. In patients 2, 3, 5, and 6 haloperidol was suspended. In patient 2 escitalopram was withdrawn as well. Finally, bromperidol was stopped in patient 7.

5. Discussion

The efficacy and safety of the combination ziprasidone- clozapine in patients with schizophrenia have been proved in previous studies . The efficacy of ziprasidone as monotherapy or in combination with mood stabilizers in patients with bipolar I disorder has been previously reported . Conversely, other authors failed to show efficacy of ziprasidone for different bipolar phases .

To our knowledge, this is the first study to evaluate efficacy and tolerability of the clozapine-ziprasidone combination for persistent mood instability and psychotic symptoms in bipolar patients with burdensome overweight and other treatment emergent side effects.

The augmentation of clozapine with ziprasidone was associated with unequivocal improvements of both psychotic and affective symptoms. In fact, all of the patients showed a score reduction on different BPRS domains and amelioration of depressive symptoms as assessed by the HAM-D. Our findings confirm previous reports suggesting a possible antidepressant effect of ziprasidone in patients suffering from bipolar type I or type II depression . Furthermore, we noticed that the addition of ziprasidone alleviated the clinical burden of clozapine related side effects such as sialorrhea and weight gain.

In our sample, only one patient with comorbid panic disorder worsened after the addition of ziprasidone because of an increase of the HAM-D anxiety score. This may suggest caution or a different dosage titration of ziprasidone in subjects with anxiety symptoms, slightly in contrast with prior open-label and placebo-controlled evidences of ziprasidone efficacy in refractory generalized anxiety disorder (GAD) . However, in the double-blind controlled study on GAD, ziprasidone was prescribed to lower flexible doses (i.e., 20–80 mg versus 80–160 daily in our report).

Kaushik et al. described the case of a patient aged 43 with schizoaffective disorder who had showed psychomotor activation after the prescription of high dose ziprasidone treatment. After nine days of ziprasidone monotherapy (at a dose of 320 mg/day), the authors reported the appearance of psychomotor restlessness, irritability, anxiety, and akathisia . According to the data available in the literature and based on what we observed in our sample, as well as in relation to the pharmacodynamics of ziprasidone, it could be argued that lower doses are associated with more anxiolytic properties and fewer extrapyramidal side effects while higher doses may be associated with akathisia and the loss of anxiolytic effects.

As shown by the nonlinear variations of clozapine/norclozapine plasma levels before and after ziprasidone introduction, the efficacy of ziprasidone was not related to a pharmacokinetic interaction with clozapine. Accordingly, Ziegenbein et al. (2005) have demonstrated that clozapine and ziprasidone undergo different metabolic pathways, with the former metabolized by the cytochrome P450 system and the latter mostly through aldehyde oxidation .

The additional dopamine D2 antagonistic action of ziprasidone may enhance the relatively weak D2 blockade exerted by clozapine and partially explain the clinical improvement produced by this combination. Furthermore, ziprasidone displays serotonin and noradrenaline reuptake inhibition properties and 5HT1C agonist activity ; this is offering other reasonable explanations for its benefits on mood and psychomotor symptomatology.

Ziprasidone was well tolerated in all of the patients. No patient needed to stop the drug due to treatment emergent side effects. Adjunctive ziprasidone resulted in a BMI reduction in the vast majority of subjects, according to other published findings , except for those two patients who had a normal BMI at the initial assessment. Moreover, Ziprasidone was associated with the withdrawal of concomitant antipsychotics in all the patients but two (see Table 2). These findings are promisingly in keeping with results from schizophrenia trials and small studies suggesting that ziprasidone may allow a dose reduction/discontinuation of coprescribed medications, decrease appetite, and even bring about a sizeable weight loss .

6. Study Limitations

This is a small naturalistic short-term case series of the clozapine-ziprasidone combination for severe psychotic bipolar patients. The promising results we have shown both in improved efficacy and in tolerability need to be confirmed in larger size and longer-term studies focused also on relapse prevention and assessment of global functioning. Given that clozapine is not indicated for bipolar disorder and should be considered an exceptional rescue treatment, it is unlikely that controlled trials will be performed. Therefore, our choices will have to rely mostly on clinical experience and case reports. In future, a more precise evaluation of psychopathological dimensions (e.g. energy levels, mood, proneness to psychosis, sleep, etc.) affected by ziprasidone augmentation will help to refine our opinion on this therapeutic strategy. In the absence of other risk factors for QTc prolongation/cardiac arrhythmias, ziprasidone prescription does not demand electrocardiogram monitoring . Nevertheless, it would be interesting to add information about QTc variations in next studies, as Kuwilsky et al. (2010) have already recorded a statistically significant QTc elongation in schizophrenic patients treated with the clozapine-ziprasidone association .

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

About the author

Leave a Reply

Your email address will not be published. Required fields are marked *